Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Tugues, Sònia ^a,f   Roche, Francis ^a   Noguer, Oriol ^a   Orlova, Anna ^b   Bhoi, Sujata ^a   Padhan, Narendra ^a   Akerud, Peter ^c   Honjo, Satoshi ^a   Selvaraju, Ram Kumar ^b   Mazzone, Massimiliano ^d,e   Tolmachev, Vladimir ^a   Claesson Welsh, Lena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; COLONY STIMULATING FACTOR 1; GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; IODINE 125; IODINE HISTIDINE RICH GLYCOPROTEIN I 125; MESSENGER RNA; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; HISTIDINE-RICH PROTEINS; PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; CANCER GROWTH; CANCER STAGING; CELL DIFFERENTIATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; ISOTOPE LABELING; MALE; METASTASIS; MICROAUTORADIOGRAPHY; MOLECULAR DYNAMICS; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PURIFICATION; PROTEIN TRANSPORT; STEADY STATE; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; U937 CELL LINE; ANIMAL; FIBROSARCOMA; INFLAMMATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHAGOCYTE; STROMA CELL; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD45; CELL LINE, TUMOR; FIBROSARCOMA; HUMANS; INFLAMMATION; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHAGOCYTES; PROTEIN BINDING; PROTEINS; STROMAL CELLS; TISSUE DISTRIBUTION;

EID: 84907270565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107483     Document Type: Article

References (31)

1. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, et al. (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
2. Shannon O, Rydengard V, Schmidtchen A, Morgelin M, Alm P, et al. (2010) Histidine-rich glycoprotein promotes bacterial entrapment in clots and decreases mortality in a mouse model of sepsis. Blood 116: 2365-2372.
3. Abrahamson M, Alvarez-Fernandez M, Nathanson CM (2003) Cystatins. Biochem Soc Symp: 179-199.
4. Lee C, Bongcam-Rudloff E, Sollner C, Jahnen-Dechent W, Claesson-Welsh L (2009) Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein. Front Biosci 14: 2911-2922.
5. Poon IK, Patel KK, Davis DS, Parish CR, Hulett MD (2011) Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood 117: 2093-2101.
6. Vanwildemeersch M, Olsson AK, Gottfridsson E, Claesson-Welsh L, Lindahl U, et al. (2006) The anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner. J Biol Chem 281: 10298-10304.
7. Wakabayashi S (2013) New insights into the functions of histidine-rich glycoprotein. Int Rev Cell Mol Biol 304: 467-493.
8. Borza DB, Tatum FM, Morgan WT (1996) Domain structure and conformation of histidine-proline-rich glycoprotein. Biochemistry 35: 1925-1934.
9. Koide T, Foster D, Yoshitake S, Davie EW (1986) Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 25: 2220-2225.
10. Leebeek FW, Kluft C, Knot EA, De Maat MP (1989) Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. J Lab Clin Med 113: 493-497.
11. Morgan WT (1986) Serum histidine-rich glycoprotein levels are decreased in acquired immune deficiency syndrome and by steroid therapy. Biochem Med Metab Biol 36: 210-213.
12. Saito H, Goodnough LT, Boyle JM, Heimburger N (1982) Reduced histidinerich glycoprotein levels in plasma of patients with advanced liver cirrhosis. Possible implications for enhanced fibrinolysis. Am J Med 73: 179-182.
13. Tsuchida-Straeten N, Ensslen S, Schafer C, Woltje M, Denecke B, et al. (2005) Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 3: 865-872.
14. Chang NS, Leu RW, Rummage JA, Anderson JK, Mole JE (1992) Regulation of macrophage Fc receptor expression and phagocytosis by histidine-rich glycoprotein. Immunology 77: 532-538.
15. Rydengard V, Shannon O, Lundqvist K, Kacprzyk L, Chalupka A, et al. (2008) Histidine-rich glycoprotein protects from systemic Candida infection. PLoS Pathog 4: e1000116.
16. Tugues S, Honjo S, Konig C, Noguer O, Hedlund M, et al. (2012) Genetic Deficiency in Plasma Protein HRG Enhances Tumor Growth and Metastasis by Exacerbating Immune Escape and Vessel Abnormalization. Cancer Res 72: 1953-1963.
17. Olsson AK, Larsson H, Dixelius J, Johansson I, Lee C, et al. (2004) A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 64: 599-605.
18. Poon IK, Olsson AK, Hulett MD, Parish CR (2009) Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage. Biochem J 424: 27-37.
19. Moore S, Spackman DH, Stein WH (1958) Automatic recording apparatus for use in the chromatography of amino acids. Fed Proc 17: 1107-1115.
20. Dixelius J, Olsson AK, Thulin A, Lee C, Johansson I, et al. (2006) Minimal active domain and mechanism of action of the angiogenesis inhibitor histidinerich glycoprotein. Cancer Res 66: 2089-2097.
21. Olsson I, Gullberg U, Ivhed I, Nilsson K (1983) Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha, 25-dihydroxycholecalciferol. Cancer Res 43: 5862-5867.
22. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67.
23. Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS (2011) Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nucl Med 52: 625-633.
24. Vayrynen JP, Tuomisto A, Klintrup K, Makela J, Karttunen TJ, et al. (2013) Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer 109: 1839-1847.
25. Mamoune A, Saraux A, Delaunay JL, Le Goff P, Youinou P, et al. (1998) Autoantibodies to CD45 in systemic lupus erythematosus. J Autoimmun 11: 485-488.
26. Hume DA, MacDonald KP (2012) Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119: 1810-1820.
27. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, et al. (2003) A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 101: 1155-1163.
28. Hashimoto D, Miller J, Merad M (2011) Dendritic cell and macrophage heterogeneity in vivo. Immunity 35: 323-335.
29. Lijnen HR, Hoylaerts M, Collen D (1980) Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 255: 10214-10222.
30. Lijnen HR, DeCock F, Collen D (1981) Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. Thromb Res 23: 121-131.
31. McFarlane (1958) Efficient trace-labelling of proteins with iodine. Nature 182: 53.